Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today ...
Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...
In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...
Research from WashU Medicine found a possible new treatment strategy for certain types of blood cancers. The bone marrow of a mouse with a myeloproliferative neoplasm (left) shows fibrosis, or scar ...
The following is a summary of “Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation,” published in the December ...
While the absolute risk of melanoma by age 40 remained low, survivors of childhood cancer exhibited a standardized incidence ...
A 41-year-old woman with no significant past medical history presents with a solitary nodule on her lower left ankle. The lesion has been growing over the past several months. The patient first ...
A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that ...
The researchers estimated the 30-year cumulative incidence of any cutaneous malignant neoplasm to be 27.4%. Patients who have undergone blood or marrow transplantation (BMT) are at significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback